A team of scientists led by Liang Ge from Tsinghua University have identified a chaperonin subunit CCT2 as a new type of aggrephagy receptor which specifically accelerates the autophagic clearance of solid aggregates independent of ubiquitination, providing a promising therapeutic target for neurodegenerative diseases.

Carthera SA reported results from a pilot clinical trial to evaluate the safety and efficacy of its Sonocloud technology in patients with mild Alzheimer’s disease (AD). The results, published in Alzheimer’s Research and Therapy, show early promise of the treatment in reducing the amyloid load of AD and potentially other neurological conditions as well as to stimulate neurogenesis and improve cognitive performance.